e-ISSN 1309-2545      ISSN 1301-062X

Download Current Issue.

Volume : 29 Issue : 3 Year : 2023

Current Issue Archive Popular Articles Ahead of Print Submit Your Article Login Copyright Transfer Form
Turkish Journal of Neurology Indexed By
  Botulinum Toxin Treatment in Blepharospasm: Single-center Experience [Turk J Neurol]
Turk J Neurol. 2023; 29(3): 204-208 | DOI: 10.4274/tnd.2023.91979  

Botulinum Toxin Treatment in Blepharospasm: Single-center Experience

Arman Çakar1, Bedia Samancı2, Haşmet Ayhan Hanağası2, Yeşim Parman1
1Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Division of Neuromuscular, Istanbul, Türkiye
2Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Division of Behavioral Neurology and Movement Disorders, Istanbul, Türkiye

Objective: Blepharospasm (BS) is a focal dystonia that affects periocular muscles such as the orbicularis oculi, procerus, and corrugator. The disease may occur in isolation or in the course of neurodegenerative diseases, and its first-line treatment is the administration of botulinum toxin. In this study, we aim to analyze the clinical features of patients with BS.
Materials and Methods: In this study, the clinical features and treatment responses of patients with BS were retrospectively analyzed.
Results: Of the 49 patients included in the study, 23 were female and 26 were male. The mean age at administration was 56.8 ± 10.8 (between 35 and 85 years), and the mean age of onset was 52.2 ± 11.9 (between 21 and 82 years). Fourteen patients had a diagnosis of a neurodegenerative disease. Fourteen patients had additional oral treatment for their symptoms. The most common oral treatments were anticholinergic drugs, benzodiazepines, and antiepileptics. The mean unit of botulinum toxin was 32.4 ± 5.8 (15.0–42.5). Treatment response was evaluated in 42 patients. Of these, 36 (86%) had either good or excellent benefit. The mean duration of treatment benefit was 105.35 ± 36.35 (between 30 and 180) days. Pretarsal application was associated with better and more prolonged treatment response than preseptal. Other analyzed clinical parameters showed no effect on the benefit of botulinum toxin. Side effects were observed in seven patients, and the most common were orbicularis oculi weakness, ecchymosis, and xerophthalmia.
Conclusion: Our study demonstrated that botulinum toxin is effective and safe in the treatment of BS. Although pretarsal application has a similar side-effect profile to preseptal application, it was associated with better and longer treatment benefit.

Keywords: Dystonia, focal, Meige Syndrome, pretarsal, neurodegenerative

Arman Çakar, Bedia Samancı, Haşmet Ayhan Hanağası, Yeşim Parman. Botulinum Toxin Treatment in Blepharospasm: Single-center Experience. Turk J Neurol. 2023; 29(3): 204-208

Corresponding Author: Arman Çakar, Türkiye

English Full Text
Download citation
Reference Manager
Share with email
Send email to author

Similar articles
Google Scholar

© Copyright 2023 Turkish Journal of Neurology
Home        |        Contact
LookUs & OnlineMakale